Hypertrophic cardiomyopathy

Cardiac Electrophysiology Clinics

Volumn 2, Issue 4, 2010, Pages 587-598

  Critoph, Christopher ^a   Elliott, Perry ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Arrhythmia; Heart failure; Hypertrophic cardiomyopathy; Sarcomere proteins; Stroke; Sudden death

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DIURETIC AGENT; GADOLINIUM; VERAPAMIL;

AMBULATORY MONITORING; ARTIFICIAL HEART PACEMAKER; BACTERIAL ENDOCARDITIS; CLINICAL FEATURE; CLINICAL PRACTICE; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST; DISEASE COURSE; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; EXERCISE TEST; FAMILIAL DISEASE; FAMILY COUNSELING; GENE MUTATION; GENETIC COUNSELING; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART CATHETERIZATION; HEART DEATH; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART PACING; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE SEPTUM; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MUSCLE RESECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SCREENING TEST; STROKE; SUDDEN DEATH; THORAX PAIN;

EID: 78649432278     PISSN: 18779182     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccep.2010.09.010     Document Type: Review

References (86)

1. Elliott P., Andersson B., Arbustini E., et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008, 29(2):270-276.
2. Maron B.J., Gardin J.M., Flack J.M., et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995, 92(4):785-789.
3. Marian A.J., Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol 2001, 33(4):655-670.
4. Richard P., Charron P., Carrier L., et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. EUROGENE heart failure project. Circulation 2003, 107(17):2227-2232.
5. Seidman J.G., Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001, 104(4):557-567.
6. Maron B.J., Estes N.A., Maron M.S., et al. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation 2003, 107(23):2872-2875.
7. Maron B.J., McKenna W.J., Danielson G.K., et al. Task force on clinical expert consensus documents. American College of Cardiology; Committee for Practice Guidelines. European Society of Cardiology. J Am Coll Cardiol 2003, 42(9):1687-1713.
8. Thaman R., Gimeno J.R., Murphy R.T., et al. Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart 2005, 91(7):920-925.
9. Kubo T., Gimeno J.R., Bahl A., et al. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J Am Coll Cardiol 2007, 49(25):2419-2426.
10. Alcalai R., Seidman J.G., Seidman C.E. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol 2008, 19(1):104-110.
11. Perkins M.J., Van Driest S.L., Ellsworth E.G. Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy. Eur Heart J 2005, 26(22):2457-2462.
12. Lind J.M., Chiu C., Ingles J., et al. Sex hormone receptor gene variation associated with phenotype in male hypertrophic cardiomyopathy patients. J Mol Cell Cardiol 2008, 45(2):217-222.
13. Nagai T., Ogimoto A., Okayama H., et al. A985G polymorphism of the endothelin-2 gene and atrial fibrillation in patients with hypertrophic cardiomyopathy. Circ J 2007, 71(12):1932-1936.
14. Tartaglia M., Gelb B.D. Noonan syndrome and related disorders: genetics and pathogenesis. Annu Rev Genomics Hum Genet 2005, 6:45-68.
15. Noonan J.A. Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am J Dis Child 1968, 116(4):373-380.
16. Sharland M., Burch M., McKenna W.M., et al. A clinical study of Noonan syndrome. Arch Dis Child 1992, 67(2):178-183.
17. Tartaglia M., Mehler E.L., Goldberg R., et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001, 29(4):465-468.
18. Tartaglia M., Pennacchio L.A., Zhao C., et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 2007, 39(1):75-79.
19. Roberts A.E., Araki T., Swanson K.D., et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 2007, 39(1):70-74.
20. Schubbert S., Zenker M., Rowe S.L., et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet 2006, 38(3):331-336.
21. Pandit B., Sarkozy A., Pennacchio L.A., et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 2007, 39(8):1007-1012.
22. Razzaque M.A., Nishizawa T., Komoike Y., et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet 2007, 39(8):1013-1017.
23. Digilio M.C., Conti E., Sarkozy A., et al. Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 2002, 71(2):389-394.
24. Linhart A., Elliott P.M. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 2007, 93(4):528-535.
25. Nishino I., Fu J., Tanji K., et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 2000, 406(6798):906-910.
26. Danon M.J., Oh S.J., DiMauro S., et al. Lysosomal glycogen storage disease with normal acid maltase. Neurology 1981, 31(1):51-57.
27. Sugie K., Yamamoto A., Murayama K., et al. Clinicopathological features of genetically confirmed Danon disease. Neurology 2002, 58(12):1773-1778.
28. Katzin L.W., Amato A.A. Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy. J Clin Neuromuscul Dis 2008, 9(4):421-431.
29. Klinge L., Straub V., Neudorf U., et al. Enzyme replacement therapy in classical infantile Pompe disease: results of a ten-month follow-up study. Neuropediatrics 2005, 36(1):6-11.
30. Blair E., Redwood C., Ashrafian H., et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 2001, 10(11):1215-1220.
31. Murphy R.T., Mogensen J., McGarry K., et al. Adenosine monophosphate-activated protein kinase disease mimics hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history. J Am Coll Cardiol 2005, 45(6):922-930.
32. Scaglia F., Towbin J.A., Craigen W.J., et al. Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease. Pediatrics 2004, 114(4):925-931.
33. Holmgren D., Wåhlander H., Eriksson B.O., et al. Cardiomyopathy in children with mitochondrial disease; clinical course and cardiological findings. Eur Heart J 2003, 24(3):280-288.
34. Alper G., Narayanan V. Friedreich's ataxia. Pediatr Neurol 2003, 28(5):335-341.
35. Child J.S., Perloff J.K., Bach P.M., et al. Cardiac involvement in Friedreich's ataxia: a clinical study of 75 patients. J Am Coll Cardiol 1986, 7(6):1370-1378.
36. Casazza F., Ferrari F., Piccone U., et al. Progression of cardiopathology in Friedreich ataxia: clinico-instrumental study. Cardiologia 1990, 35(5):423-431.
37. Davies M.J., McKenna W.J. Hypertrophic cardiomyopathy-pathology and pathogenesis. Histopathology 1995, 26(6):493-500.
38. Hughes S.E. The pathology of hypertrophic cardiomyopathy. Histopathology 2004, 44(5):412-427.
39. Maron B.J., Wolfson J.K., Epstein S.E., et al. Intramural (" small vessel" ) coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986, 8(3):545-557.
40. Counihan P.J., Frenneaux M.P., Webb D.J., et al. Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy. Circulation 1991, 84(2):686-696.
41. Elliott P., McKenna W.J. Hypertrophic cardiomyopathy. Lancet 2004, 363(9424):1881-1891.
42. Yamaguchi H., Ishimura T., Nishiyama S., et al. Hypertrophic nonobstructive cardiomyopathy with giant negative T waves (apical hypertrophy): ventriculographic and echocardiographic features in 30 patients. Am J Cardiol 1979, 44(3):401-412.
43. Fananapazir L., Tracy C.M., Leon M.B., et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation 1989, 80(5):1259-1268.
44. Krikler D.M., Davies M.J., Rowland E., et al. Sudden death in hypertrophic cardiomyopathy: associated accessory atrioventricular pathways. Br Heart J 1980, 43(3):245-251.
45. Klues H.G., Schiffers A., Maron B.J. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995, 26(7):1699-1708.
46. Maron B.J., Gottdiener J.S., Epstein S.E. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol 1981, 48(3):418-428.
47. Shapiro L.M., McKenna W.J. Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. J Am Coll Cardiol 1983, 2(3):437-444.
48. Wigle E.D., Sasson Z., Henderson M.A., et al. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy [a review]. Prog Cardiovasc Dis 1985, 28(1):1-83.
49. Maron M.S., Olivotto I., Zenovich A.G., et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006, 114(21):2232-2239.
50. Shah J.S., Esteban M.T., Thaman R., et al. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart 2008, 94(10):1288-1294.
51. Robert A., Levine M.D., Gus J., et al. Papillary muscle displacement causes systolic anterior motion of the mitral valve; experimental validation and insights into the mechanism of subaortic obstruction. Circulation 1995, 91:1189-1195.
52. Kramer C.M., Reichek N., Ferrari V.A., et al. Regional heterogeneity of function in hypertrophic cardiomyopathy. Circulation 1994, 90(1):186-194.
53. Choudhury L., Mahrholdt H., Wagner A., et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002, 40(12):2156-2164.
54. Moon J.C., McKenna W.J., McCrohon J.A., et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003, 41(9):1561-1567.
55. O'Hanlon R., Grasso A., Roughton M., et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 2010, 56(11):867-874.
56. Jones S., Elliott P.M., Sharma S., et al. Cardiopulmonary responses to exercise in patients with hypertrophic cardiomyopathy. Heart 1998, 80(1):60-67.
57. Sharma S., Elliott P.M., Whyte G., et al. Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. J Am Coll Cardiol 2000, 36(3):864-870.
58. Olivotto I., Maron B.J., Montereggi A., et al. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999, 33(7):2044-2051.
59. Sadoul N., Prasad K., Elliott P.M., et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997, 96(9):2987-2991.
60. Ciampi Q., Betocchi S., Lombardi R., et al. Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy. J Am Coll Cardiol 2002, 40(2):278-284.
61. Elliott P.M., Poloniecki J., Dickie S., et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000, 36(7):2212-2218.
62. Monserrat L., Elliott P.M., Gimeno J.R., et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003, 42(5):873-879.
63. Sanghvi N.K., Tracy C.M. Sustained ventricular tachycardia in apical hypertrophic cardiomyopathy, midcavitary obstruction, and apical aneurysm. Pacing Clin Electrophysiol 2007, 30(6):799-803.
64. Olivotto I., Cecchi F., Casey S.A., et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001, 104(21):2517-2524.
65. Robinson K., Frenneaux M.P., Stockins B., et al. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol 1990, 15(6):1279-1285.
66. Maron B.J., Casey S.A., Hauser R.G., et al. Clinical course of hypertrophic cardiomyopathy with survival to advanced age. J Am Coll Cardiol 2003, 42(5):882-888.
67. Maron B.J., Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am J Cardiol 1993, 72(12):970-972.
68. Colan S.D., Lipshultz S.E., Lowe A.M., et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation 2007, 115(6):773-781.
69. Maron B.J. Hypertrophic cardiomyopathy in childhood. Pediatr Clin North Am 2004, 51(5):1305-1346.
70. Spirito P., Chiarella F., Carratino L., et al. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med 1989, 320(12):749-755.
71. Spirito P., Rapezzi C., Autore C., et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 1994, 90(6):2743-2747.
72. Spirito P., Maron B.J., Bonow R.O., et al. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in patients with hypertrophic cardiomyopathy. Am J Cardiol 1987, 60:123-129.
73. Maron B.J., Olivotto I., Bellone P., et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002, 39(2):301-307.
74. Spirito P., Rapezzi C., Bellone P., et al. Infective endocarditis in hypertrophic cardiomyopathy: prevalence, incidence, and indications for antibiotic prophylaxis. Circulation 1999, 99(16):2132-2137.
75. Maron B.J., Nishimura R.A., McKenna W.J., et al. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 1999, 99(22):2927-2933.
76. Maron B.J. Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy. Lancet 2000, 355(9202):425-426.
77. Merrill W.H., Friesinger G.C., Graham T.P., et al. Long-lasting improvement after septal myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg 2000, 69(6):1732-1735. [discussion: 1735-6].
78. Maron B.J., Shirani J., Poliac L.C., et al. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 1996, 276(3):199-204.
79. Elliott P.M., Sharma S., Varnava A., et al. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999, 33(6):1596-1601.
80. Dilsizian V., Bonow R.O., Epstein S.E., et al. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1993, 22(3):796-804.
81. Frenneaux M.P. Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy. Heart 2004, 90(5):570-575.
82. Garratt C.J., Elliott P., Behr E., et al. Heart rhythm UK Familial Sudden Cardiac Death Syndromes Statement Development Group. Heart rhythm UK position statement on clinical indications for implantable cardioverter defibrillators in adult patients with familial sudden cardiac death syndromes. Europace 2010, 12(8):1156-1175.
83. Behr E.R., Elliott P., McKenna W.J. Role of invasive EP testing in the evaluation and management of hypertrophic cardiomyopathy. Card Electrophysiol Rev 2002, 6(4):482-486.
84. Saumarez R.C., Pytkowski M., Sterlinski M., et al. Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy. Eur Heart J 2008, 29(13):1653-1661.
85. Autore C., Conte M.R., Piccininno M., et al. Risk associated with pregnancy in hypertrophic cardiomyopathy. J Am Coll Cardiol 2002, 40(10):1864-1869.
86. Thaman R., Varnava A., Hamid M.S., et al. Pregnancy related complications in women with hypertrophic cardiomyopathy. Heart 2003, 89(7):752-756.